Investing.com - Ionis Pharma reported on Wednesday third quarter earnings that beat analysts' forecasts and revenue that topped expectations. Ionis Pharma announced earnings per...
Ionis Pharmaceuticals (IONS) reported Q3 EPS of ($0.33), $0.39 better than the analyst estimate of ($0.72). Revenue for the quarter came in at $160 million versus the consensus...
Cathie Wood announced the upcoming closure of the ARK Transparency ETF Despite declines, investors continue to follow Wood’s holdings closely Consider 2 Ark Invest ETFs that...
USANA Health (NYSE:USNA) Sciences Inc. USNA is scheduled to report second-quarter 2020 results on Jul 21, aftermarketclose. The company flaunts a mixedearningssurprise history,...
Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY) announced that the European Commission has approved Givlaari (givosiran) for the treatment of acute hepatic porphyria (AHP) in patients...
Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an injection for the treatment of polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; and WAYLIVRA, a treatment for familial chylomicronemia syndrome and familial partial lipodystrophy. It also develops medicines for various indications that are in phase 3 study, including Eplontersen as a monthly self-administered subcutaneous injection to treat all types of TTR amyloidosis; Olezarsen for patients with severe hypertriglyceridemia (SHTG); Donidalorsen for patients with hereditary angioedema; ION363 for patients with amyotrophic lateral sclerosis; Pelacarsen for patients with established cardiovascular disease and elevated lipoprotein(a); and Tofersen to inhibit the production of superoxide dismutase 1. In addition, the company develops medicines for metabolic diseases, infectious diseases, renal diseases, ophthalmic diseases, and cancer. It has a strategic collaboration with Biogen Inc.; and collaboration and license agreement with AstraZeneca, Bayer AG, GlaxoSmithKline plc, Novartis AG, Roche, Janssen Biotech, Inc., and Flamingo Therapeutics, Inc. Ionis Pharmaceuticals, Inc. was founded in 1989 and is based in Carlsbad, California.
|Average||50.263 (+27.35% Upside)|
|No. of Analysts||19|